Cancer Expanded Access Plans Need Focus On Data Collection – FDA’s Pazdur

Expanded access programs for cancer products should be limited in scope to gather data on use in patients with refractory disease, FDA Oncologic Drug Products Division Director Richard Pazdur, MD, said at the American Society of Clinical Oncology annual meeting in Orlando May 18